Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Chemed's Roto-Rooter & VITAS Robust, Acuity Mix Shift Weak

Published 07/16/2019, 08:39 AM
Updated 07/09/2023, 06:31 AM
MSFT
-
MSI
-
NUVA
-
CHE
-
TFX
-
PEN
-

On Jul 15, we issued an updated research report on Chemed Corporation (NYSE:CHE) . The company currently operates two wholly-owned subsidiaries, namely VITAS Healthcare and Roto-Rooter.

Over the past three months, shares of Chemed have consistently outperformed its industry. The stock has gained 9.5% compared with the industry’s 3.5% rise. Chemed exited 2018 on a promising note. The company generated strong year-over-year growth in revenues. It is optimistic to note that it witnessed a solid revenue uptick across its key subsidiaries.

VITAS has been registering an expanded average daily census. Moreover, the Roto-Rooter business has been seeing growth on the back of a solid performance by the core plumbing and drain cleaning service segments as well as a robust trend in water restoration.

Moreover, we are upbeat about Roto-Rooter, which is currently the nation's leading provider of plumbing and drain cleaning services. Through its network of company-owned branches, independent contractors and franchises, Roto-Rooter offers plumbing and drain cleaning services to more than 90% of the U.S. population.

On the flip side, Chemed ended first-quarter 2019 on a dull note. Both earnings and revenues missed the respective Zacks Consensus Estimate in the reported quarter. An unfavorable acuity mix shift, fluctuations in net room and board plus contractual adjustments dented the top line during the period.

Chemed's capital deployment policy is based on its suitable buyouts and a solid return of cash to shareholders through dividends and buybacks.

Zack Rank and Key Picks

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Chemed currently curries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are Teleflex Inc. (NYSE:TFX) , Penumbra (NYSE:PEN) and NuVasive Corporation (NASDAQ:NUVA) . While Teleflex currently carries a Zacks Rank #2 (Buy), the other two sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Teleflex’s long-term earnings growth rate is expected at 13.7%.

Penumbra’s long-term earnings growth rate is projected at 21.5%.

NuVasive’s long-term earnings growth rate is expected to be 11.9%.

Radical New Technology Creates $12.3 Trillion Opportunity

Imagine buying Microsoft (NASDAQ:MSFT) stock in the early days of personal computers… or Motorola (NYSE:MSI) after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors. Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.

See the 7 breakthrough stocks now>>



Teleflex Incorporated (TFX): Free Stock Analysis Report

Penumbra, Inc. (PEN): Free Stock Analysis Report

NuVasive, Inc. (NUVA): Free Stock Analysis Report

Chemed Corporation (CHE): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.